Literature DB >> 3371456

Macrophages exposed in vitro to conduritol B epoxide resemble Gaucher cells.

D S Newburg1, T B Shea, S Yatziv, S S Raghavan, R H McCluer.   

Abstract

In Gaucher disease the genetic lack of acid beta-glucosidase activity causes glucocerebroside to accumulate in the lysosomes of macrophage-derived cells, producing large characteristic Gaucher cells. The formation of Gaucher cells seems to be central to the pathobiology of this lysosomal storage disease. To develop a model simulating this process, cultured murine peritoneal macrophages were treated with conduritol B epoxide, a specific irreversible inhibitor of acid beta-glucosidase, for 6, 15, and 24 days. The conduritol B epoxide-treated macrophages accumulated glucocerebroside as a function of time, progressing to a fivefold elevation over control values after 24 days of treatment. Electron microscopy of the cells treated for 24 days reveals characteristics of Gaucher cells, including striations consisting of oriented fibrils. With conventional staining techniques, these fibrils have an appearance considered highly characteristic of Gaucher disease. Thus, macrophages treated with conduritol B epoxide are a useful model for studying the metabolic consequences and morphologic features associated with glucocerebroside accumulation in Gaucher cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3371456     DOI: 10.1016/0014-4800(88)90068-8

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  6 in total

1.  Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.

Authors:  U H Schueler; T Kolter; C R Kaneski; G C Zirzow; K Sandhoff; R O Brady
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Screening and optimization of ligand conjugates for lysosomal targeting.

Authors:  Igor Meerovich; Alexander Koshkaryev; Ritesh Thekkedath; Vladimir P Torchilin
Journal:  Bioconjug Chem       Date:  2011-10-06       Impact factor: 4.774

3.  β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.

Authors:  Christina M Ridley; Karen E Thur; Jessica Shanahan; Nagendra Babu Thillaiappan; Ann Shen; Karly Uhl; Charlotte M Walden; Ahad A Rahim; Simon N Waddington; Frances M Platt; Aarnoud C van der Spoel
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

4.  Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.

Authors:  Ritesh Thekkedath; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2012-12-02       Impact factor: 5.307

5.  Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients.

Authors:  Catia S Pereira; Begoña Pérez-Cabezas; Helena Ribeiro; M Luz Maia; M Teresa Cardoso; Ana F Dias; Olga Azevedo; M Fatima Ferreira; Paula Garcia; Esmeralda Rodrigues; Paulo Castro-Chaves; Esmeralda Martins; Patricio Aguiar; Mercè Pineda; Yasmina Amraoui; Simona Fecarotta; Elisa Leão-Teles; Shenglou Deng; Paul B Savage; M Fatima Macedo
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

6.  In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.

Authors:  Chi-Lin Kuo; Wouter W Kallemeijn; Lindsey T Lelieveld; Mina Mirzaian; Iris Zoutendijk; Ayelet Vardi; Anthony H Futerman; Annemarie H Meijer; Herman P Spaink; Herman S Overkleeft; Johannes M F G Aerts; Marta Artola
Journal:  FEBS J       Date:  2019-02-02       Impact factor: 5.542

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.